Ingevity Toekomstige groei
Future criteriumcontroles 3/6
De verwachting is dat Ingevity de winst en omzet met respectievelijk 46.9% en 0.07% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 55.1% per jaar.
Belangrijke informatie
46.9%
Groei van de winst
55.13%
Groei van de winst per aandeel
| Chemicals winstgroei | 21.7% |
| Inkomstengroei | 0.07% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 04 Sep 2026 |
Recente toekomstige groei-updates
Recent updates
Seeking Alpha • Aug 28
Ingevity: Portfolio Simplification Reveals A High-Margin Regulatory Compounder
Summary Ingevity is transforming into a focused, high-margin regulatory compounder, emphasizing Performance Materials and Pavement Technologies after divesting volatile, lower-quality segments. Q2 '26 results highlight margin inflection: adjusted EBITDA rose 14% to $115M, margin expanded to 36.6%, and EPS increased to $1.74, demonstrating strong operating leverage. Hybrid vehicle adoption and infrastructure spending underpin resilient demand for NGVT’s emissions-control and pavement solutions, while PFAS filtration offers incremental EBITDA growth optionality. NGVT trades at a discount on EV/EBITDA versus peers, but improved business quality and robust free cash flow support a bullish outlook despite EV transition and leverage risks. Read the full article on Seeking AlphaAnalyse-artikel • Aug 07
Ingevity (NYSE:NGVT) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Ingevity Corporation's ( NYSE:NGVT ) solid earnings announcement recently didn't do much to the stock price. We did...
Narratiefupdate • Jul 04
NGVT: Share Repurchases And 2026 Guidance Will Support Future P/E Rerating
Analysts have modestly raised their price target for Ingevity to $89.0 from $85.5, citing updated assumptions that include a smaller expected revenue decline, a slightly lower discount rate, and a marginally reduced profit margin and future P/E ratio. What’s in the News for Ingevity Ingevity reaffirmed full year 2026 earnings guidance, with expected net sales in a range of $1.05b to $1.15b.Analyse-artikel • Jun 18
Ingevity (NGVT) Stock Could Be 14% Undervalued on Its Portfolio Reshaping Narrative
Ingevity (NGVT) stock has been in focus after recent trading performance, prompting investors to reassess how the company’s materials and specialty chemicals portfolio lines up with its current valuation and recent share price moves. See our latest analysis for Ingevity. At a share price of $73.41, Ingevity has seen a 12.90% 1 month share price return and a 22.17% year to date share price return, while its 1 year total shareholder return of 77.40% points to momentum that has been building...Narratiefupdate • Jun 13
NGVT: Portfolio Reshaping And Buybacks Will Support Future P/E Re Rating
Analysts have maintained their $85.50 price target for Ingevity, citing largely stable assumptions around the discount rate, revenue growth, profit margin, and future P/E as the basis for keeping their current view. What's in the News Ingevity completed the sale of its Ozark Materials Road Markings product line and divested its North Charleston CTO refinery and most of the Industrial Specialties product line, as part of a portfolio reshaping effort.Narratiefupdate • May 29
NGVT: Share Repurchases And Margin Strength Will Support Future P/E Re Rating
Analysts have maintained their $85.50 price target on Ingevity, citing consistent assumptions for revenue growth, profit margins, discount rate, and future P/E as the basis for their view. What's in the News From January 1, 2026 to March 31, 2026, Ingevity repurchased 774,189 shares, representing 2.18% of its stock, for a total of $51.94 million under its ongoing buyback program announced on August 2, 2022 (Key Developments).Narratiefupdate • May 14
NGVT: Future P/E Will Reward Margin Strength Despite Recent Impairment Charge
Analysts have raised Ingevity's price target from $80.50 to $85.50, citing updated assumptions for discount rates, revenue growth, profit margins, and future P/E that they believe more accurately reflect the stock's risk and earnings profile. What's in the News Ingevity reaffirmed earnings guidance for full year 2026, with expected net sales in a range of $1.05b to $1.15b (company guidance).Narratiefupdate • Apr 28
NGVT: Future P/E Will Reflect Margin Resilience And Impairment Charge Impact
Analysts have increased their price target for Ingevity to $80.50 from $79.25, citing updated assumptions on long term revenue growth, profit margin resilience, and future P/E levels reflected in recent research, including the Wells Fargo target increase. Analyst Commentary Recent research behind the new US$80.50 price target focuses on refreshed assumptions for long term revenue trends, margin resilience, and the P/E level that investors may be willing to ascribe to Ingevity over time.Narratiefupdate • Apr 11
NGVT: Future P/E Will Depend On Margin Execution And Impairment Fallout
Analysts have raised their price target on Ingevity by $5 to $79.25, citing updated assumptions regarding discount rates, long-term revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts raising the price target to $79.25 are updating their models to reflect changes in discount rates, long term revenue assumptions, profit margins, and future P/E expectations.Narratiefupdate • Mar 28
NGVT: Higher P/E Will Rely On Future Margin Delivery
Analysts have lifted their price target on Ingevity by $5 to $79.25, citing updated assumptions on discount rates, long term revenue growth, profit margins, and future P/E, which support a slightly higher valuation outlook. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as consistent with updated assumptions on discount rates and long term revenue growth, which they believe better reflect the company’s current risk profile and earnings potential.Narratiefupdate • Mar 13
NGVT: Higher P/E Outlook Will Depend On Margin Execution
Analysts have raised their price target on Ingevity by $8.50 to $79.25, citing updated views on revenue growth, profit margins, and an expected higher future P/E multiple. Analyst Commentary Recent Street research has focused on how Ingevity might justify a higher valuation, with specific attention on revenue trends, profitability, and the potential for the shares to support a richer P/E multiple over time.Narratiefupdate • Feb 24
NGVT: Updated P/E Assumptions And Buybacks Will Shape Balanced Outlook
Analysts have raised their price target on Ingevity by $5 to $70.75, citing updated assumptions around discount rates and future P/E as the main factors behind this revised view. Analyst Commentary Analysts framing the new US$70.75 price target are focusing less on short term headlines and more on what updated discount rate and P/E assumptions imply for Ingevity's risk profile and execution needs.Narratiefupdate • Feb 09
NGVT: Share Repurchases And Battery Materials License Will Guide Balanced Outlook
Analysts have raised their price target on Ingevity from US$69.50 to US$70.75, citing updated assumptions around discount rates, revenue trends, profit margins and future P/E expectations. Analyst Commentary Analysts who support the higher price target describe it as a fine tuning of their models rather than a wholesale rethink.Narratiefupdate • Jan 26
NGVT: Buybacks And Battery Materials License Will Shape Balanced Outlook
Analysts have maintained their fair value estimate for Ingevity at US$69.50, with only minor adjustments to inputs such as the discount rate and long-term P/E assumptions. These changes reflect updated modeling rather than a change in conviction.Narratiefupdate • Jan 10
NGVT: Battery Additives And Buybacks Will Shape Balanced Long-Term Outlook
Analysts have adjusted their price target on Ingevity to US$69.50. This reflects updated views on the discount rate, revenue outlook, profit margins and future P/E assumptions.Narratiefupdate • Dec 25
NGVT: Future Battery Materials Role Will Drive Long-Term Upside Despite Margin Reset
Analysts have modestly raised their price target on Ingevity by about $1.25 to approximately $69.50. They cite a lower perceived discount rate and an improving revenue trajectory, which more than offset concerns about a structurally lower profit margin and a higher future valuation multiple.Narratiefupdate • Dec 10
NGVT: Future Battery Materials Role Will Drive Stronger Long Term Upside Potential
Analysts have nudged their price target on Ingevity higher from $65.25 to $68.25, citing a modestly richer future earnings multiple that more than offsets slightly softer revenue growth and margin assumptions. What's in the News Ingevity announced that Executive Vice President and Chief Financial Officer Mary Dean Hall will transition from her role effective May 1, 2026, and remain in an advisory capacity for one year, as part of a planned leadership change.Analyse-artikel • Sep 30
Is There Now An Opportunity In Ingevity Corporation (NYSE:NGVT)?
While Ingevity Corporation ( NYSE:NGVT ) might not have the largest market cap around , it received a lot of attention...Analyse-artikel • Sep 06
Does Ingevity (NYSE:NGVT) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Narratiefupdate • Sep 05
Portfolio Repositioning And Engineered Additives Will Create A Sustainable Future
Consensus analyst price targets for Ingevity have risen to $65.25, reflecting increased confidence in continued earnings and free cash flow growth following a strong Q2 beat and improved operational outlook. Analyst Commentary Q2 earnings beat, demonstrating stronger-than-expected financial performance.Narratiefupdate • Aug 06
Portfolio Repositioning And Engineered Additives Will Create A Sustainable Future
The upward revision in Ingevity's revenue growth forecasts from 2.6% to 3.7% per annum has outweighed the impact of a higher discount rate, resulting in an increased consensus analyst price target from $54.25 to $57.00. What's in the News Ingevity Corporation maintained its earnings guidance for 2025, expecting sales between $1.25 billion and $1.40 billion.Analyse-artikel • Jun 27
Ingevity Corporation (NYSE:NGVT) Shares Could Be 39% Below Their Intrinsic Value Estimate
Key Insights The projected fair value for Ingevity is US$71.30 based on 2 Stage Free Cash Flow to Equity Ingevity's...Analyse-artikel • May 28
Subdued Growth No Barrier To Ingevity Corporation (NYSE:NGVT) With Shares Advancing 33%
Those holding Ingevity Corporation ( NYSE:NGVT ) shares would be relieved that the share price has rebounded 33% in the...Nieuw narratief • May 27
Premium Markets Will Secure Long Term Value
Expansion into premium specialty chemicals and advanced materials is increasing margins and positioning for growth as sustainability trends and vehicle electrification accelerate.Analyse-artikel • Apr 05
Why We're Not Concerned Yet About Ingevity Corporation's (NYSE:NGVT) 32% Share Price Plunge
Ingevity Corporation ( NYSE:NGVT ) shares have had a horrible month, losing 32% after a relatively good period...Analyse-artikel • Feb 20
Ingevity (NYSE:NGVT) Has A Somewhat Strained Balance Sheet
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analyse-artikel • Jan 16
Ingevity Corporation (NYSE:NGVT) Shares Could Be 49% Below Their Intrinsic Value Estimate
Key Insights Ingevity's estimated fair value is US$82.84 based on 2 Stage Free Cash Flow to Equity Ingevity is...Analyse-artikel • Nov 07
What Ingevity Corporation's (NYSE:NGVT) 32% Share Price Gain Is Not Telling You
Ingevity Corporation ( NYSE:NGVT ) shareholders have had their patience rewarded with a 32% share price jump in the...Analyse-artikel • Oct 13
Is Ingevity (NYSE:NGVT) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyse-artikel • Sep 08
Ingevity Corporation's (NYSE:NGVT) Prospects Need A Boost To Lift Shares
When you see that almost half of the companies in the Chemicals industry in the United States have price-to-sales...Seeking Alpha • Aug 27
Ingevity: The Risk-Reward Ratio Is Still Unfavorable
Summary Ingevity, once considered a growth story, turned out to be a classic example of market cycles. While Road Technology and Performance Materials performed reasonably well in the first half of 2024, the Industrial Specialties segment dragged down revenue and net income. Given the company's significant debt burden, risk-averse investors should seek safer options within the chemical industry. Read the full article on Seeking AlphaAnalyse-artikel • Aug 03
Ingevity Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
There's been a notable change in appetite for Ingevity Corporation ( NYSE:NGVT ) shares in the week since its quarterly...Analyse-artikel • Jul 13
Ingevity (NYSE:NGVT) Use Of Debt Could Be Considered Risky
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyse-artikel • Jun 14
Should You Investigate Ingevity Corporation (NYSE:NGVT) At US$45.90?
Ingevity Corporation ( NYSE:NGVT ), might not be a large cap stock, but it received a lot of attention from a...Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2028 | 1,153 | 214 | 262 | 314 | 2 |
| 12/31/2027 | 1,130 | 199 | 250 | 302 | 3 |
| 12/31/2026 | 1,110 | 157 | 240 | 288 | 3 |
| 6/30/2026 | 1,160 | 25 | 155 | 211 | N/A |
| 3/31/2026 | 1,178 | -156 | 246 | 304 | N/A |
| 12/31/2025 | 1,168 | -150 | 274 | 331 | N/A |
| 9/30/2025 | 1,176 | -52 | 240 | 299 | N/A |
| 6/30/2025 | 1,177 | -45 | 150 | 215 | N/A |
| 3/31/2025 | 1,108 | -36 | 95 | 166 | N/A |
| 12/31/2024 | 1,200 | -121 | 51 | 129 | N/A |
| 9/30/2024 | 1,309 | -258 | 28 | 110 | N/A |
| 6/30/2024 | 1,421 | -280 | 72 | 169 | N/A |
| 3/31/2024 | 1,640 | -112 | 87 | 188 | N/A |
| 12/31/2023 | 1,216 | 106 | 95 | 205 | N/A |
| 9/30/2023 | 1,704 | 127 | 128 | 257 | N/A |
| 6/30/2023 | 1,740 | 177 | 120 | 252 | N/A |
| 3/31/2023 | 1,678 | 202 | 154 | 294 | N/A |
| 12/31/2022 | 1,668 | 212 | 171 | 313 | N/A |
| 9/30/2022 | 1,621 | 225 | 160 | 291 | N/A |
| 6/30/2022 | 1,516 | 146 | 171 | 291 | N/A |
| 3/31/2022 | 1,454 | 130 | 152 | 266 | N/A |
| 12/31/2021 | 1,392 | 118 | 190 | 293 | N/A |
| 9/30/2021 | 1,381 | 135 | 273 | 370 | N/A |
| 6/30/2021 | 1,336 | 209 | 272 | 360 | N/A |
| 3/31/2021 | 1,248 | 185 | 264 | 343 | N/A |
| 12/31/2020 | 1,216 | 181 | 270 | 352 | N/A |
| 9/30/2020 | 1,194 | 180 | 199 | 285 | N/A |
| 6/30/2020 | 1,222 | 170 | 222 | 313 | N/A |
| 3/31/2020 | 1,304 | 206 | N/A | 344 | N/A |
| 12/31/2019 | 1,293 | 184 | N/A | 276 | N/A |
| 9/30/2019 | 1,268 | 182 | N/A | 276 | N/A |
| 6/30/2019 | 1,219 | 171 | N/A | 252 | N/A |
| 3/31/2019 | 1,175 | 161 | N/A | 234 | N/A |
| 12/31/2018 | 1,134 | 169 | N/A | 252 | N/A |
| 9/30/2018 | 1,085 | 169 | N/A | 207 | N/A |
| 6/30/2018 | 1,037 | 153 | N/A | 193 | N/A |
| 3/31/2018 | 989 | 138 | N/A | 178 | N/A |
| 12/31/2017 | 972 | 127 | N/A | 174 | N/A |
| 9/30/2017 | 954 | 94 | N/A | 187 | N/A |
| 6/30/2017 | 942 | 53 | N/A | 144 | N/A |
| 3/31/2017 | 927 | 45 | N/A | 131 | N/A |
| 12/31/2016 | 908 | 35 | N/A | 128 | N/A |
| 9/30/2016 | 898 | 34 | N/A | 111 | N/A |
| 6/30/2016 | 902 | 64 | N/A | 100 | N/A |
| 3/31/2016 | 919 | 66 | N/A | 92 | N/A |
| 12/31/2015 | 958 | 80 | N/A | 72 | N/A |
| 9/30/2015 | 999 | 99 | N/A | 76 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei NGVT ( 46.9% per jaar) ligt boven de spaarquote ( 3.7% ).
Winst versus markt: De winst van NGVT ( 46.9% per jaar) zal naar verwachting sneller groeien dan de US markt ( 17.3% per jaar).
Hoge groeiwinsten: De winst van NGVT zal naar verwachting de komende 3 jaar aanzienlijk groeien.
Omzet versus markt: De omzet van NGVT ( 0.07% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 13.5% per jaar).
Hoge groei-inkomsten: De omzet van NGVT ( 0.07% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van NGVT naar verwachting over 3 jaar hoog zal zijn
Ontdek groeibedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/09/10 05:10 |
| Aandelenkoers aan het einde van de dag | 2026/09/10 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Ingevity Corporation wordt gevolgd door 7 analisten. 3 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Paretosh Misra | Berenberg |
| John McNulty | BMO Capital Markets Equity Research |
| Jonathan Tanwanteng | CJS Securities, Inc. |